Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 9
in 15 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Olema Pharmaceuticals’ loss per share trailed expectations in the second fiscal quarter of 2026, based on preliminary results reported August 10, 2026, with EPS of -$0.61 coming in below the -$0.55 estimate (difference -$0.06) and down from -$0.51 a year ago. The clinical-stage women’s oncology biotech posted net income of -$63.2 million, a -44.3% year-over-year change versus -$43.8 million in the prior-year period, alongside operating income of -$67.2 million. Cash use remained heavy, with negative operating cash flow of -$45.9 million for the quarter as the company continued advancing its OP-1250 program in breast cancer. Consensus for the next period calls for EPS of -$0.60 on revenue of $1.2 million.
Next report — what to expect
Olema Pharmaceuticals, Inc. (OLMA) reports next on November 9, 2026. Wall Street expects EPS of -$0.60 on revenue of $1.2 million. In recent history, Olema has beaten EPS in 3 of its 8 most recent quarters, so traders may focus on results versus these consensus benchmarks.
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on women's oncology. The company develops therapeutic candidates for breast cancer and related hormone-driven disease settings, and it operates as a small-cap clinical-stage business based in healthcare. Olema has been public since its 2020 NASDAQ debut.
Today's Snapshot
The day ended with OLMA 8.7% lower at 6.41, in line with a weaker sector. Volume was about a quarter more than its usual level.
Trading Volume
Above 10d avg 1.4M
1.9M
vs S&P 500 Today
Strong Underperformance
-8.17%
Updated: October 23, 2026 at 20:23 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$7.07 - $14.05Sell
- RSI (14)25.44Buy
- Stochastic %K (14, 3, 3)22.04Neutral
- MACD Level (12, 26)-0.73Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.